What insurance policy changes affect code Z67.91?

There are 2 tracked policy changes affecting code Z67.91, including updates from Aetna. Each change may modify coverage criteria, reimbursement rates, or prior-authorization requirements.

Which payers have updated policy for code Z67.91?

Payers that have issued tracked updates for code Z67.91 include: Aetna.

How do I get notified when code Z67.91 policy changes?

Create a free account at PolicyChanges.app and save a search filtered to code Z67.91. You will get an email when new policy changes reference this code: daily or weekly, your choice, on every plan.

Why do payers change policies for code Z67.91?

Payers revise policies for individual billing codes to align with updated clinical guidelines, CMS rule changes, fraud and abuse prevention measures, or network cost-management goals. Changes can affect medical necessity criteria, place-of-service restrictions, bundling rules, or whether a code requires prior authorization.

PAYER POLICY CHANGES

Z67.91 Insurance Policy Changes

ICD-10 Z67.91 is officially defined as "Unspecified blood type, Rh negative." code Z67.91 is referenced in 2 tracked payer policy changes from Aetna. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for code Z67.91 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

Only a small number of policies match this filter. Check back as coverage expands.

Aetna · Identified Oct 10, 2026Medium impact
Immune Globulins for Post-Exposure Prophylaxis (CPB 0544, reviewed 2026-10-07)
Aetna considers immune globulins medically necessary for hepatitis B, cytomegalovirus, Rho-D, rabies, varicella zoster, tetanus, vaccinia, botulism, hepatitis A, measles (rubeola) and rubella exposures or conditions, and considers all other indications experimental, investigational, or unproven. Each product has its own initial criteria, such as hepatitis B immune globulin for members who had contact with an individual diagnosed with hepatitis B virus, Rho-D immune globulin for unsensitized Rh-negative women at 24 to 28 weeks gestation unless the father is known to be Rh-negative, and varicella zoster immune globulin for high-risk individuals with significant exposure to varicella. Continuation of therapy for each product is considered medically necessary for all members, including new members, who meet all initial medical necessity criteria.
Aetna · Identified Aug 15, 2026Medium impact
Immune Globulins for Post-Exposure Prophylaxis (CPB 0544, reviewed 2025-12-23)
Reviewed 2025-12-23, Aetna Clinical Policy Bulletin 0544 covers immune globulin products for post-exposure prophylaxis and treatment, including hepatitis B, cytomegalovirus, Rho(D), rabies, varicella zoster, tetanus, measles, rubella, vaccinia, and botulism immune globulins. For each product the policy lists the indications it considers medically necessary and states that all other indications are experimental, investigational, or unproven. Continuation of therapy is considered medically necessary for all members, including new members, who meet the initial criteria. Immune globulin intramuscular injection (GamaSTAN) requires precertification.

Watch Z67.91

Get one email when a payer policy names Z67.91, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.

Get alerts for changes like this

Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.

Create a free alert How Policy Monitoring works

Immune Globulins for Post-Exposure Prophylaxis (CPB 0544, reviewed 2026-10-07)

Immune Globulins for Post-Exposure Prophylaxis (CPB 0544, reviewed 2025-12-23)

What insurance policy changes affect code Z67.91?

Which payers have updated policy for code Z67.91?

How do I get notified when code Z67.91 policy changes?

Why do payers change policies for code Z67.91?